Trials that are temporarily unblinded are never reported on. If the data is spectacular, they may recommend ending the trial early, and that would be reported. If the data was bad, they would recommend halting the trial for futility. If they are satisfied with the data, then the trial just continues.
I don't believe that the company sees details, they just see the recommendation which normally is to continue. Peeks at the data rarely end the trial early for efficacy, but occasionally it will happen.
Gary